Drug intelligence / Profile preview

1-(4-thiophen-2-ylphenyl)methanamine

Development stage: Unknown
Modality: Small Molecules

Overview

1-(4-thiophen-2-ylphenyl)methanamine is an experimental small molecule compound with the chemical formula C11H11NS and a molecular weight of approximately 189.28 g/mol[3][4]. It features a phenylethylamine core substituted with a thiophene ring at the para position. The compound acts as an inhibitor of leukotriene A4 hydrolase, an enzyme involved in the biosynthesis of leukotriene B4—a potent pro-inflammatory mediator—suggesting potential anti-inflammatory properties[2][6]. There are no approved indications or clinical trials reported for this molecule; it remains at the experimental stage and is not approved for medical use[2].

Other names: 1-[4-(2-thienyl)phenyl]methanamine(4-thiophen-2-ylphenyl)methanamineBenzenemethanamine, 4-(2-thienyl)-

Targets

LTA4H (Leukotriene A4 hydrolase)

Beyond the preview

Go deeper on 1-(4-thiophen-2-ylphenyl)methanamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1-(4-thiophen-2-ylphenyl)methanamine.

Explore the full profile